Related Experiment Videos
[Recent advances in Parkinson disease]
1Unidad de Neurofarmacología, Henry M. Jackson Foundation, Bethesda, MD, USA. litvan1@helix.nih.gov
Revista De Neurologia
|October 21, 1999
Summary
Levodopa remains the cornerstone for Parkinson's disease treatment. Newer drugs like dopaminergic agonists and COMT inhibitors offer valuable options for managing early and advanced stages of this neurodegenerative disorder.
Area of Science:
- Neurology
- Pharmacology
Background:
- Parkinson's disease (PD) diagnosis relies on clinical criteria informed by clinico-pathological studies.
- Symptomatic treatment of PD requires ongoing evaluation of therapeutic options.
Purpose of the Study:
- To review recent advancements in diagnosing Parkinson's disease.
- To assess current pharmacological treatments for Parkinson's disease across different disease stages.
Main Methods:
- Review of clinico-pathological studies for diagnostic criteria.
- Evaluation of controlled, double-blind studies on PD pharmacotherapy.
- Comparison of efficacy for dopaminergic agonists (carbergolin, pramipexol, ropinirol) and COMT inhibitors (entacapone, tolcapone) against placebo and established treatments (levodopa, bromocriptine).
Main Results:
- Levodopa is identified as a primary treatment for Parkinson's disease.
- Newer dopaminergic agonists and catechol-O-methyl-transferase (COMT) inhibitors demonstrate efficacy in managing PD symptoms.
- These newer agents are effective in both early and late stages of Parkinson's disease.
Conclusions:
- Levodopa continues to be the most significant treatment for Parkinson's disease.
- Dopaminergic agonists and COMT inhibitors represent valuable additions to the therapeutic arsenal for Parkinson's disease.
- Current treatment guidelines for Parkinson's disease should incorporate these advanced pharmacological options.